Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24476493 | 0.80 | FAAH (0.48) | TSHRCYP3A4CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL24476284 | 0.80 | KAT2B (0.40) | TSHR | |
| SCHEMBL24476531 | 0.78 | — | — | |
| SCHEMBL24476587 | 0.77 | CSNK2A1 (0.32) | CSNK2A1 | |
| SCHEMBL24476358 | 0.77 | TSHR (0.33) | TSHRKMT2ACSNK2A1PIM1CSNK2A2 | |
| SCHEMBL24476318 | 0.77 | TSHR (0.33) | TSHRKMT2ACSNK2A1PIM1CSNK2A2 | |
| SCHEMBL31625100 | 0.71 | KDM4E (0.38) | KDM4E | |
| SCHEMBL15600397 | 0.71 | KDM4E (0.38) | KDM4E | |
| SCHEMBL8464465 | 0.71 | TK1 (0.51) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10871605 | 0.68 | PNP (0.59) | TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| CN-113645977-A | Compounds, compositions and methods for treatment of disease | F-星治疗公司 | 2021-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, CGAS, MAVS | TSHR 3225/4885CYP3A4 4749/4885SMN1; SMN2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.